For a patient with recurrent ascites refractory to maximal medical therapy, what surgical interventions are recommended and what criteria determine eligibility for transjugular intra‑hepatic portosystemic shunt (TIPS) versus peritoneovenous shunt?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Recurrent Ascites: TIPS vs. Peritoneovenous Shunt

For patients with recurrent ascites refractory to maximal medical therapy, TIPS should be the primary surgical intervention, while peritoneovenous shunt should only be considered as a last resort for patients who are not candidates for TIPS or liver transplantation. 1

Primary Approach: Serial Large-Volume Paracentesis

Before considering surgical interventions, patients with refractory ascites should be managed with:

  • Serial large-volume paracentesis (LVP) with albumin infusion (8 g per liter of ascites removed for volumes >5L) 1
  • Continuation of low-salt diet
  • Maintenance of diuretics if tolerated (refractory ascites is NOT a contraindication to diuretics) 1

This approach serves as the bridge to definitive therapy, particularly for transplant candidates with short waiting times (<3-6 months). 2

TIPS: The Preferred Surgical Intervention

TIPS should be strongly considered in selected patients with refractory or recurrent ascites (defined as ascites recurring ≥3 times within 12 months despite adequate diuretic treatment). 1, 2, 3

Evidence Supporting TIPS

The most recent 2025 EASL guidelines provide the strongest recommendation: TIPS should be discussed early in patients receiving repeated LVP despite optimal medical therapy to improve outcomes including reduced decompensation, need for transplant, and death. 3 The 2021 Gut guidelines (high-quality evidence, strong recommendation) similarly endorse TIPS for refractory ascites. 1

Key benefits of TIPS:

  • Superior long-term ascites control (85% at 3 years vs. 40% with peritoneovenous shunt) 4
  • Improved transplant-free survival compared to LVP 2
  • Reduced healthcare utilization (fewer emergency visits and hospitalizations) 5
  • Cost-effective (savings of €25,687 to £17,983 per patient) 3

Patient Selection Criteria for TIPS

Absolute contraindications: 1, 2, 6

  • Overt recurrent/chronic hepatic encephalopathy
  • Severe pulmonary hypertension (mean PAP >35 mmHg, PVR >240 dyn·cm⁻⁵)
  • Congestive heart failure or ejection fraction <50%
  • Severe cardiac diastolic/valvular dysfunction
  • Active sepsis/infection

Relative contraindications (use caution): 1, 2

  • Age >70 years
  • Serum bilirubin >50 μmol/L
  • Platelet count <75×10⁹/L
  • MELD score ≥18
  • Pre-existing hepatic encephalopathy
  • Hepatorenal syndrome

Critical point: While MELD ≥18 is traditionally considered a relative contraindication, the 2021 expert review notes that this threshold is increasingly being challenged, and MELD should be used in conjunction with holistic assessment including age, frailty, and comorbidities rather than as an absolute cutoff. 2

Pre-TIPS Evaluation Required

  • Echocardiography to assess cardiac systolic/diastolic function and right ventricular systolic pressure 6
  • Ensure right ventricular systolic pressure <45 mmHg 6
  • Screen for active infection
  • Assess for prior hepatic encephalopathy

Timing of TIPS

Early TIPS strategy: Some evidence suggests TIPS after just 3 large-volume paracenteses in 12 months may be beneficial, particularly in patients with other indications (e.g., prior variceal bleeding), though this requires further validation. 6 For transplant candidates, TIPS should only be undertaken after discussion with the regional transplant center. 7

Peritoneovenous Shunt: Last Resort Only

Peritoneovenous shunt should be considered ONLY for patients who: 8, 9

  • Are NOT candidates for liver transplantation
  • Are NOT candidates for TIPS (due to contraindications listed above)
  • Have poor access to serial LVP
  • Have abdominal wounds that limit serial LVP

Evidence Against Peritoneovenous Shunt

The Korean guidelines explicitly state that peritoneovenous shunt "causes many procedure-related complications and offers no benefit over medical treatment in terms of survival." 8 While a 2004 randomized trial showed peritoneovenous shunts provide faster initial ascites control (73% vs. 46% at 1 month), TIPS demonstrated superior long-term efficacy and assisted patency. 4

Key limitations:

  • High rate of shunt occlusion (38% irreversible occlusion vs. 19% with TIPS) 4
  • Shorter median survival (16.1 months vs. 28.7 months with TIPS) 4
  • Numerous complications including disseminated intravascular coagulation and heart failure 6
  • Poor long-term patency requiring frequent interventions 4

A 2021 study showed peritoneovenous shunt had the shortest transplant-free survival (44 days) compared to TIPS (155 days) and LVP (213 days), though it remained an acceptable alternative when TIPS is contraindicated. 5

Algorithm for Decision-Making

  1. Confirm refractory ascites: Ascites unresponsive to maximum diuretics (spironolactone 400 mg + furosemide 160 mg daily) with sodium restriction, OR diuretic-intolerant

  2. Immediate referral for liver transplant evaluation (refractory ascites is a transplant indication) 8

  3. If transplant candidate with short wait time (<3-6 months):

    • Continue serial LVP with albumin as bridge to transplant 2

  4. If longer wait time or not immediate transplant candidate:

    • Assess TIPS eligibility using criteria above
    • If TIPS eligible: Proceed with TIPS (preferably with polytetrafluoroethylene-covered stents) 1, 2, 3
    • If TIPS contraindicated: Continue serial LVP with albumin

  5. Only if TIPS contraindicated AND poor LVP access:

    • Consider peritoneovenous shunt as palliative measure 8, 9
    • Alternative: Indwelling peritoneal catheter or alfapump (recently FDA-approved automated low-flow ascites pump), though experience is limited 6

Common Pitfalls to Avoid

  • Do not withhold TIPS based solely on MELD ≥18: Use comprehensive assessment including functional status and comorbidities 2
  • Do not stop diuretics after TIPS: TIPS converts diuretic-resistant patients to diuretic-sensitive; continue diuretics and titrate to achieve natriuresis 9
  • Do not use peritoneovenous shunt as first-line surgical therapy: It should only be considered when TIPS and transplant are not options 8, 9
  • Do not forget cardiac evaluation before TIPS: Cardiac decompensation occurs in up to 20% within 1 year post-TIPS 6
  • Do not confuse refractory with recurrent ascites: Recurrent/recidivant ascites (≥3 episodes in 12 months) has stronger evidence for TIPS benefit than truly refractory ascites 2

Special Considerations

For patients with hepatic hydrothorax: TIPS should be considered after multidisciplinary discussion, with similar selection criteria as for ascites. 1, 7

Beta-blocker management: Refractory ascites is NOT a contraindication to non-selective beta-blockers, but close monitoring of blood pressure and renal function is required, with dose reduction or discontinuation if hypotension or progressive renal dysfunction develops. 8, 1

Palliative care: Patients with refractory ascites who are not undergoing transplant evaluation should be offered palliative care referral. 1

References

3
Guideline

easl clinical practice guidelines on tips.

Journal of Hepatology, 2025

Related Questions

What is the recommended outpatient management for ascites, including low‑sodium diet, diuretic regimen, and criteria for therapeutic paracentesis or TIPS?
How should recurrent ascites be managed in a cirrhotic patient who is receiving hospice care?
What antibiotic is safe to use in a patient with chronic liver disease, ascites, and hepatitis?
Can a patient with abdominal ascites, normal liver function tests, hemoglobin 8.6 g/dL, and who stopped drinking alcohol five years ago still have alcoholic cirrhosis?
How should ascites due to cirrhosis be diagnosed and managed?
What is the most likely unifying diagnosis for a patient presenting with severe hypokalemia, toxic hyperthyroidism, medullary nephrocalcinosis, and nephrolithiasis?
How sensitive is hemoglobin A1c (HbA1c) in patients with chronic liver disease, particularly those with cirrhosis or significant portal hypertension?
What is the ASA physical status classification, peri‑operative thrombo‑embolic (TECH) risk, and appropriate thromboprophylaxis for a planned total thyroidectomy in a 48‑year‑old patient with well‑controlled hypertension (home readings ≤135/80 mmHg), mild structural cardiac changes on echocardiography, autoimmune thyroiditis in euthyroid state, and a BMI of 25.2 kg/m²?
What does a hypoechoic finding on an abdominal and pelvic ultrasound indicate and what are the recommended next steps?
What are the symptoms of a right frontal periventricular infarct?
How should a hypoechoic mass measuring about 3.4 × 3.5 × 3.5 cm in the left iliac fossa detected on abdominal and pelvic ultrasound be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.